Last reviewed · How we verify
Aflibercept IVT
Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability.
Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability. Used for Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration).
At a glance
| Generic name | Aflibercept IVT |
|---|---|
| Also known as | Eylea |
| Sponsor | 4D Molecular Therapeutics |
| Drug class | VEGF trap; anti-angiogenic fusion protein |
| Target | VEGF-A, VEGF-B, PlGF (placental growth factor) |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Aflibercept functions as a soluble decoy receptor containing VEGF-binding domains from VEGFR1 and VEGFR2 fused to the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents their interaction with endogenous VEGF receptors on endothelial cells, thereby reducing abnormal blood vessel formation and leakage characteristic of retinal and choroidal diseases. The intravitreal formulation (IVT) delivers the drug directly to the eye for treatment of retinal pathologies.
Approved indications
- Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration)
Common side effects
- Conjunctival hemorrhage
- Eye pain or discomfort
- Floaters
- Intraocular inflammation
- Endophthalmitis (rare)
Key clinical trials
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (PHASE3)
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
- High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
- A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
- Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) (PHASE3)
- A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aflibercept IVT CI brief — competitive landscape report
- Aflibercept IVT updates RSS · CI watch RSS
- 4D Molecular Therapeutics portfolio CI